Queensland Brain Institute

PathMaker Neurosystems Announces Completion of Pivotal European Clinical Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity

Retrieved on: 
Monday, September 27, 2021
Clinical trial, MTS, Stroke, Queensland Brain Institute, Health, Amyotrophic lateral sclerosis, FDA, IRB, Institute, Spasticity, Patient, APHP, NSR, Disability, Connective tissue disease, Station F, Heart, GLOBE, US Foods, Food and Drug Administration, Cerebral palsy, CNRS, Neurotoxin, Multiple sclerosis, ALS, Brain, ICM, Safety, INSERM, Traumatic brain injury, Sorbonne University, Lists of diseases, Pharmaceutical industry, Medical device

This clinical trial was conducted at the Paris Brain Institute (ICM) in the Piti-Salptrire Hospital in Paris, France and was sponsored by INSERM.

Key Points: 
  • This clinical trial was conducted at the Paris Brain Institute (ICM) in the Piti-Salptrire Hospital in Paris, France and was sponsored by INSERM.
  • We are pleased to have completed this clinical trial to evaluate our MyoRegulator device, commented Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker.
  • Completion of this trial is an important step in advancing this product as a novel approach to the treatment of spasticity that does not require injected neurotoxins or sedating pharmaceuticals.
  • MyoRegulator will be the worlds first non-invasive neuromodulation device for the treatment for muscle spasticity, and will enable the treatment of patients without the need for drugs or surgery.

UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity

Retrieved on: 
Monday, June 7, 2021
Health sciences, Health, Articles, Drug discovery, Druggability, Queensland Brain Institute, Virus

Furthermore, our data highlight that certain changes in protein expression levels, namely Orf9b, may have significant impact on the virus-host interaction.

Key Points: 
  • Furthermore, our data highlight that certain changes in protein expression levels, namely Orf9b, may have significant impact on the virus-host interaction.
  • In identifying the key pathway and proteins responsible for pathogenesis, we have uncovered druggable targets with high therapeutic value.
  • However, QBI and University of College researchers discovered striking differences with respect to the host response to these viruses.
  • About QBI: The Quantitative Biosciences Institute (QBI) is a University of Californiaorganizedresearchunitreporting through the UCSF School ofPharmacy.

Qbi Toy Unveils Qbi Explorer, a New Learning System for Kids

Retrieved on: 
Monday, November 30, 2020
Queensland Brain Institute, University of Queensland, Toy, Puzzle

TAIPEI, Nov. 30, 2020 /PRNewswire/ -- Qbi Toy announced the launch of the Qbi Explorer Collection, an interactive puzzle for kids available in preschool and kids packs.

Key Points: 
  • TAIPEI, Nov. 30, 2020 /PRNewswire/ -- Qbi Toy announced the launch of the Qbi Explorer Collection, an interactive puzzle for kids available in preschool and kids packs.
  • Designed to harness children's enjoyment of puzzles, it allows kids to create their own constructive learning experience where the adventure is different each time.
  • Qbi Explorer teaches kids STEM concepts in a method approved by parents and teachers.
  • With Qbi Explorer, kids maintain a sense of spatial and tactile awareness rather than the tunnel vision that accompanies standard 2D puzzles or video games.

Ascensus Expands California Presence with Agreement to Acquire QBI, LLC

Retrieved on: 
Wednesday, June 27, 2018
Personal finance, Economy, Finance, Money, Coverdell Education Savings Account, Queensland Brain Institute, Pension, Ascensus, Inc.

DRESHER, Pa., June 27, 2018 /PRNewswire/ -- Ascensus , a technology-enabled solutions provider that helps more than 8 million Americans save for the future, has entered into an agreement to acquire QBI, LLC (QBI).

Key Points: 
  • DRESHER, Pa., June 27, 2018 /PRNewswire/ -- Ascensus , a technology-enabled solutions provider that helps more than 8 million Americans save for the future, has entered into an agreement to acquire QBI, LLC (QBI).
  • Based in Woodland Hills, California, QBI is one of the largest administrators of defined contribution and defined benefit plans in the country.
  • "In addition, their strong presence in California allows us to increase our footprint in a region that is geographically attractive to us.
  • Ascensus supports over 60,000 retirement plans, more than 4 million 529 education savings accounts, and a growing number of ABLE savings accounts.